Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAPPHIRE phase 3 trial of sitravatinib + nivolumab versus docetaxel in advanced non-squamous non-small cell lung cancer
MOH_2021-03-10_009824Phase 3Completed
- Sponsor
- Mirati Therapeutics
- Start
- Feb 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Non-small cell lung cancer (NS-NSCLC) comparing sitravatinib + nivolumab with docetaxel (2 arms). Started Feb 2021; status: completed.
02
Drugs
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on MOH_2021-03-10_009824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-03-10_009824.